Sofiniclin is more potent than ABT-089 at both receptor subtypes, with Ki values of 1.3 nM for 125I-epibatidine binding and of 1.9 nM for 125I-α-conotoxinMII binding [1].

Compared to vehicle monkey, Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs [1]. Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage [2].